Late-Breaking Oral Session

(LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A

C. DiNardo, B. Jonas, V. Pullarkat, et al.

The authors conclude: 

Among treatment-naïve predominantly elderly pts with AML ineligible for intensive therapy, the combination regimen of AZA+VEN led to statistically significant and clinically meaningful improvement in response rates and OS as compared to AZA, with a manageable safety profile.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2602) PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS PHLEBOTOMY IN LOW-RISK PATIENTS WITH POLYCYTHEMIA VERA. RESULTS OF THE PRE-PLANNED INTERIM ANALYSIS

T. Barbui, A. M. Vannucchi, V. De Stefano, et al. 

The authors conclude: 

This interim analysis of Low-PV trial convincingly demonstrated that Ropeginterferon is safe and more efficacious in keeping HCT on target in low-risk PV patients. This result has been achieved with a reduction in the number of phlebotomies and with an improvement in the quality of life. 

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2603) ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

P. Moreau, M.-A. Dimopoulos, J. Mikhael, et al.

The authors conclude: 

The addition of Isa to Kd provided a superior, statistically significant improvement in PFS with clinically meaningful improvement in depth of response. Isa-Kd was well tolerated with manageable safety and a favorable benefit-risk profile and represents a possible new standard of care treatment in pts with relapsed MM.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2604) SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY

E. Kastritis, G. Palladini, M. C. Minnema, et al.

The authors conclude: 

The addition of DARA to CyBorD was superior to CyBorD alone, resulting in deeper and more rapid hematologic responses and improved clinical outcomes with an acceptable safety profile. DARA-CyBorD therapy resulted in improved MOD-PFS and substantially higher organ responses in newly diagnosed AL amyloidosis pts.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2605) ENDOTHELIOPATHY IS ESSENTIAL IN COVID-19 ASSOCIATED COAGULOPATHY

G. Goshua, A. Pine, M. Meizlish, et al.

The authors conclude: 

As measured by sTM, sP-sel, sCD40L, PAI-1, and vWF, CAC is a prothrombotic state driven by endotheliopathy and platelet activation. These processes occur early in the pathogenesis of COVID-19 infection and becomes more pronounced with worsening severity of disease. sTM levels in particular are significantly associated with mortality in ICU patients.

--------------------------------------------------------------------------------------------------------------------------------------------------------

(LB2606) REAL-TIME NATIONAL SURVEY OF COVID-19 IN HEMOGLOBINOPATHY AND RARE INHERITED ANEMIA PATIENTS

P. Telfer, J. De La Fuente, M. Sohal, et al.

The authors conclude: 

Despite guidance to reduce the risk of COVID19 in extremely vulnerable individuals by strict self-isolation at home, a significant number of hemoglobinopathy patients have been infected with SARS-CoV-2. Socioeconomic factors and nosocomial transmission may have contributed to viral transmission. The low incidence of cases in children is commensurate with the generally mild course of COVID19 in this age group suggesting that shielding may not be necessary for all children with SCD and thalassemia. The increase of mortality with age is consistent with the known age demographic effect in COVID19. Patients with chronic organ damage may be at increased risk irrespective of age. Unexpectedly, mortality due to COVID19 did not show a clear correlation with clinical severity of the underlying condition or with gender. Further analysis of accumulating data from the UK, pooled with other international registries may provide a clearer picture of the susceptibility to COVID19 and risk factors of severe outcomes in these patient groups. In the meantime we advocate caution with respect to lifting of precautions implemented to protect these patients.